Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LYB001 Vaccine in Healthy Adults
NCT05125926Phase 1Unknown
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Protein Vaccines
01
Overview
Phase 1, randomised, double-blind trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Yantai Patronus Biotech Co., Ltd. Primary endpoint: Adverse events. Status: unknown.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05125926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125926.